Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.32 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26297382 | 0.98 | NOS1 (0.38) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL8350648 | 0.98 | NOS1 (0.38) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL34507 | 0.98 | NOS1 (0.38) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| Hydrochloric Acid SCHEMBL20243055 | 0.84 | NOS1 (0.38) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| Hydrochloric Acid SCHEMBL5821232 | 0.83 | NOS1 (0.39) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| Hydrochloric Acid SCHEMBL4555756 | 0.83 | NOS1 (0.37) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| Hydrochloric Acid SCHEMBL78220 | 0.83 | NOS1 (0.37) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| Hydrochloric Acid SCHEMBL1951786 | 0.83 | NOS1 (0.37) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| Hydrochloric Acid SCHEMBL3104040 | 0.83 | NOS1 (0.37) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| Hydrochloric Acid SCHEMBL918636 | 0.83 | NOS1 (0.37) | NOS1NOS3NOS2LTA4HSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115068626-A | Protein-polymer-drug conjugates | 阿萨纳生物科技有限责任公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-105813655-B | Protein-polymer-drug conjugates | 阿萨纳生物科技有限责任公司 | 2022-03-15 | — | — | CN | disclosed |
| EP-3192529-B1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | FAULSTICH HEINZ DR (DE) | 2020-03-25 | — | — | EP | disclosed |
| EP-3485912-A1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | Faulstich, Heinz, Dr. (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-9937152-B2 | Derivative of styrene-maleic acid copolymer | Maeda, Hiroshi (JP) | 2018-04-10 | — | — | US | disclosed |
| EP-3192529-A1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | Faulstich, Heinz, Dr. (DE) | 2017-07-19 | — | — | EP | disclosed |
| EP-2416804-B1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | FAULSTICH HEINZ DR (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-20160317672-A1 | DERIVATIVE OF STYRENE-MALEIC ACID COPOLYMER | Maeda, Hiroshi (JP) | 2016-11-03 | — | — | US | disclosed |
| EP-3072910-A1 | DERIVATIVE OF STYRENE-MALEIC ACID COPOLYMER | Maeda, Hiroshi (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-20160089450-A1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-03-31 | — | — | US | disclosed |
| US-9233173-B2 | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-01-12 | — | — | US | disclosed |
| EP-2834239-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | Astrazeneca AB (SE) | 2015-02-11 | — | — | EP | disclosed |
| WO-2013150296-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-10-10 | — | — | WO | disclosed |
| US-20120100161-A1 | Amatoxin-Armed Therapeutic Cell Surface Binding Components Designed for Tumour Therapy | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2012-04-26 | — | — | US | disclosed |
| EP-2416804-A2 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | Faulstich, Heinz, Dr. (DE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115629-A2 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100161-A1 | Amatoxin-Armed Therapeutic Cell Surface Binding Components Designed for Tumour Therapy | ANTXR2, TNFSF10, ANXA5 | CA2 2000/4885GAA 1410/4885NOS1 4809/4885 |
| US-20160089450-A1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | ANTXR2, TNFSF10, ANXA5 | CA2 2000/4885GAA 1410/4885NOS1 4809/4885 |
| US-20160317672-A1 | DERIVATIVE OF STYRENE-MALEIC ACID COPOLYMER | ME3, SMN1; SMN2, SMC1A | CA2 822/4885GAA 229/4885NOS1 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.